These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

975 related items for PubMed ID: 32844196

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K, Horne M, Hagell P, Iwarsson S, Nilsson MH, Odin P.
    J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
    [Abstract] [Full Text] [Related]

  • 10. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ, Spencer CM.
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD.
    Drugs; 1998 Jul; 55 Suppl 1():23-30. PubMed ID: 9483167
    [Abstract] [Full Text] [Related]

  • 13. Long-Term Follow-Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease.
    Frequin HL, Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, van Laar T, Tissingh G, Munts AG, Dijk JM, Lang AE, Dijkgraaf MGW, Hoogland J, de Bie RMA, LEAP Study Group.
    Mov Disord; 2024 Jun; 39(6):975-982. PubMed ID: 38644623
    [Abstract] [Full Text] [Related]

  • 14. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A, Aschermann Z, Ács P, Janszky J, Kovács M, Makkos A, Harmat M, Tényi D, Karádi K, Komoly S, Takáts A, Tóth A, Nagy H, Klivényi P, Dibó G, Dézsi L, Zádori D, Annus Á, Vécsei L, Varannai L, Kovács N.
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group.
    JAMA; 2000 Oct 18; 284(15):1931-8. PubMed ID: 11035889
    [Abstract] [Full Text] [Related]

  • 18. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q, Tan Y, Xu P, Tao E, Lu Z, Pan X, Wang B, Liu C, Dong X, Tian Y, Sun X, Cattaneo C, Chen S, Shang H, XINDI Study Investigators Group.
    CNS Drugs; 2022 Nov 18; 36(11):1217-1227. PubMed ID: 36346534
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Trial of Lixisenatide in Early Parkinson's Disease.
    Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O, LIXIPARK Study Group.
    N Engl J Med; 2024 Apr 04; 390(13):1176-1185. PubMed ID: 38598572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.